Abstract
AIM—To evaluate the tolerance of hydroxyurea in children affected with sickle cell disease. DESIGN—Questionnaire study of French physicians likely to treat patients with sickle cell disease. Data were collected on 101 children with sickle cell disease, treated for a median of 22 months, 36of whom were treated for more than three years. 13 children were younger than 5 years of age at inclusion. RESULTS—Hydroxyurea was stopped for medical reasons in 11 patients: 6 failures, 1 pregnancy, 1 cutaneous rash, 1 leg ulcer, 1 lupus. Acute lymphoblastic leukaemia occurred in a girl treated for 1.5months with hydroxyurea, this short interval arguing against a causative association. One 17 year old boy had paraparesis after 8 years of treatment. CONCLUSIONS—No major short or medium term toxicity was related to hydroxyurea in this cohort of 101 children. However, the number of children treated for more than 3 years is too few to make firm conclusions on the long term tolerance of this drug.
Full Text
The Full Text of this article is available as a PDF (70.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ferster A., Vermylen C., Cornu G., Buyse M., Corazza F., Devalck C., Fondu P., Toppet M., Sariban E. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996 Sep 15;88(6):1960–1964. [PubMed] [Google Scholar]
- Jayabose S., Tugal O., Sandoval C., Patel P., Puder D., Lin T., Visintainer P. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr. 1996 Oct;129(4):559–565. doi: 10.1016/s0022-3476(96)70121-x. [DOI] [PubMed] [Google Scholar]
- Koyama T., Shibakura M., Ohsawa M., Kamiyama R., Hirosawa S. Anticoagulant effects of 1alpha,25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood. 1998 Jul 1;92(1):160–167. [PubMed] [Google Scholar]
- Maier-Redelsperger M., de Montalembert M., Flahault A., Neonato M. G., Ducrocq R., Masson M. P., Girot R., Elion J. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood. 1998 Jun 15;91(12):4472–4479. [PubMed] [Google Scholar]
- Najean Y., Rain J. D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997 Nov 1;90(9):3370–3377. [PubMed] [Google Scholar]
- Ohene-Frempong K., Smith-Whitley K. Use of hydroxyurea in children with sickle cell disease: what comes next? Semin Hematol. 1997 Jul;34(3 Suppl 3):30–41. [PubMed] [Google Scholar]
- Scott J. P., Hillery C. A., Brown E. R., Misiewicz V., Labotka R. J. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996 Jun;128(6):820–828. doi: 10.1016/s0022-3476(96)70335-9. [DOI] [PubMed] [Google Scholar]
- Sterkers Y., Preudhomme C., Laï J. L., Demory J. L., Caulier M. T., Wattel E., Bordessoule D., Bauters F., Fenaux P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998 Jan 15;91(2):616–622. [PubMed] [Google Scholar]
- Styles L. A., Lubin B., Vichinsky E., Lawrence S., Hua M., Test S., Kuypers F. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood. 1997 Apr 1;89(7):2554–2559. [PubMed] [Google Scholar]
- Triadou P., Maier-Redelsperger M., Krishnamoorty R., Deschamps A., Casadevall N., Dunda O., Ducrocq R., Elion J., Girot R., Labie D. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol. 1994 Oct;36(5):367–372. [PubMed] [Google Scholar]
- Vichinsky E. P., Lubin B. H. A cautionary note regarding hydroxyurea in sickle cell disease. Blood. 1994 Feb 15;83(4):1124–1128. [PubMed] [Google Scholar]
- Walters M. C., Patience M., Leisenring W., Eckman J. R., Scott J. P., Mentzer W. C., Davies S. C., Ohene-Frempong K., Bernaudin F., Matthews D. C. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996 Aug 8;335(6):369–376. doi: 10.1056/NEJM199608083350601. [DOI] [PubMed] [Google Scholar]
- de Montalembert M., Belloy M., Bernaudin F., Gouraud F., Capdeville R., Mardini R., Philippe N., Jais J. P., Bardakdjian J., Ducrocq R. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol. 1997 Jul-Aug;19(4):313–318. doi: 10.1097/00043426-199707000-00009. [DOI] [PubMed] [Google Scholar]